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Abstract 
Cancer results from the accumulation of multiple mutations and is 
characterized by deregulated cell mechanisms including cell growth, tissue 
invasion, angiogenesis and metastasis, being responsible for a large number of 
worldwide deaths. Malignant melanoma is the most aggressive type of human skin 
cancer, being just 5% of all skin cancer cases but accounting for over 80% of all 
skin deaths. This is primarily the result of melanoma being highly resistant to 
conventional chemotherapy. The PI3K/AKT signaling pathway is involved in many 
cell processes like survival, proliferation, growth and is one of the most mutated 
pathways in all human cancers, particularly in melanomas. FOXO3a, a 
transcriptional factor, is a crucial component of the PI3K/AKT pathway regulating 
the transcription of genes that promote apoptosis and cell cycle arrest. Following its 
activation, AKT negatively regulates FOXO3a, via phosphorylation, leading to 
FOXO3a export from the nucleus into the cytoplasm where it is ubiquitinated and is 
degraded. Consequently, if AKT is constitutively active, this enables a cancer cell to 
avoid apoptosis and to keep proliferating. The TRIB2 protein was discovered to be a 
FOXO3a repressor and is over expressed in many cancers although how TRIB2 
mediates this effect is unknown. This project evaluates TRIB2 drug resistance to a 
dual PI3K/mTOR inhibitor BEZ235 in a clinically representative in vivo BEZ235 
treatment model to confirm if our in vitro data (published and unpublished) 
correlates in a 3D in vivo model and demonstrates that AKT and TRIB2 interact in 
both in vitro cell models and in ex vivo clinical samples.   
 
Keywords: Cancer, Melanoma, TRIB2, cancer cell signaling, drug resistance. 
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Resumo 
 O cancro é a nível mundial, uma das principais causas de morte. É o 
resultado da acumulação de várias mutações ao longo do tempo, e caracteriza-se 
pela desregulação dos mecanismos celulares. Há várias características que uma 
célula normal necessita para que se tornar cancerígena, sendo designadas como 
as “hallmarks of cancer” e neste momento são conhecidas dez: resistência à morte 
celular (apoptose), serem capazes de proliferar, serem capazes de escapar à 
vigilância e destruição por parte do sistema imune, serem imortais através da sua 
contínua replicação, serem genomicamente instáveis, serem capazes de induzirem 
a angiogénese (produção de novos vasos sanguíneos), desregularem os 
mecanismos de produção de energia celular, terem a capacidade de invadir outros 
tecidos, e por fim serem capazes de metastizar.  
 Melanoma maligno, é um tipo de cancro da pele que embora não sendo o 
mais comum, contemplando apenas 5% dos casos totais de cancro da pele, é o 
tipo mais agressivo, visto que é responsável por 80% das mortes por cancro da 
pele e a idade média de aparecimento é aos 50 anos, tendo maior incidência em 
indivíduos caucasianos. Este tipo de cancro é causado pela transformação maligna 
das células produtoras de melanina, os melanócitos que se encontram situados na 
epiderme. É também caracterizado por ser dos cancros no ser humano com pior 
prognóstico, e este facto deve-se à sua rápida metastização e invasão de outros 
tecidos e ao facto de atualmente não existirem drogas eficazes para o seu 
tratamento, havendo muitos casos verificados de resistência a quimioterapêuticos 
convencionais por parte destes pacientes. Este tipo de cancro é inicialmente 
designado por melanoma in situ sendo que nesta primeira fase, o seu 
desenvolvimento ocorre horizontalmente, dentro da epiderme. Ao longo do tempo, 
o seu crescimento é em profundidade, penetrando a derme e neste caso passa a 
ser designado por melanoma invasivo. Caso a doença seja detetada até esta fase, 
o prognóstico do paciente será bom uma vez que através de intervenção cirúrgica a 
fim de remover o tumor confere cerca de 95% de taxa de sobrevivência de 5 anos 
aos pacientes. 
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 A via de sinalização PI3K/AKT está envolvida em múltiplos processos 
celulares, desde mecanismos relacionados com sobrevivência, crescimento e 
proliferação celular, e é uma das vias metabólicas mais mutadas em cancros 
humanos. PI3Ks são enzimas que desencadeiam a cascata de ativação de várias 
proteínas. A desregulação da via PI3K/AKT está associada a um elevado número 
de pacientes com melanoma, pelo que é necessário que se encontrem novas 
drogas de forma a melhorar o prognóstico dos pacientes, através da compreensão 
desta via de sinalização e dos seus componentes.  
Sendo o AKT uma quinase, identificada como estando constantemente ativa nesta 
via, e estando descrito que esta ativação por parte do PIP3 (um dos substratos das 
PI3Ks), vai fazer com que o fator de transcrição FOXO3a, responsável pela 
transcrição de genes que promovem a paragem do ciclo celular (para que sejam 
remendados erros através dos checkpoints), e a apoptose (necessária para que as 
células cancerígenas morram) seja exportado do núcleo (onde está ativo), para o 
citoplasma onde através da fosforilação por parte do AKT, vai ser ubiquitinado e 
marcado para destruição proteossomal, impedindo assim que os genes com 
características anticancerígenas sejam transcritos.  
 Por ser uma das vias mais mutadas, e por não haver terapias eficazes, a via 
PI3K/AKT está a ser alvo de vários estudos e há várias drogas a ser testadas em 
ensaios clínicos, sendo BEZ235 principal foco no meu projeto de investigação, 
tendo já sido descrito por vários autores como tendo um potencial terapêutico 
anticancerígeno, visto que é um inibidor das PI3Ks.  
 Atualmente, sabe-se que a grande maioria dos pacientes com melanoma, 
adquire ao longo do tempo resistência aos tratamentos, pelo que se tem tentado 
compreender os mecanismos envolvidos nessa resistência, de forma a saber como 
reverter este problema. 
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 É também conhecido na literatura que o TRIB2 é um gene cuja 
sobrexpressão está associada a vários tipos de cancro, entre os quais melanomas, 
estando este gene também associado a mecanismos de resistência a 
quimioterapêuticos, bem como está descrito o seu envolvimento na regulação 
negativa do FOXO3a. Não é ainda evidente de que forma é feita esta regulação, 
pelo que é crucial que haja mais investigação acerca destes mecanismos, uma vez 
que sabendo de que forma FOXO3a é inativado através do TRIB2, será possível 
encontrar uma forma de inverter esta situação. A principal hipótese colocada pelo 
nosso grupo de investigação com base em estudos feitos anteriormente, é a de que 
embora os inibidores das PI3Ks estejam a atuar, e que estas sejam de facto 
inibidas, se o TRIB2 estiver constantemente a ativar o AKT hipoteticamente através 
da fosforilação deste, o inibidor não estará a sortir o efeito desejado, pelo facto de o 
AKT estar constantemente ativo, visto que consequentemente vai inativar o 
FOXO3a, impedindo a transcrição dos genes com propriedades anticancerígenas, 
como por exemplo BIM, FasLG, p27, entre outros.  
 Neste projeto de investigação, é feita a avaliação do inibidor das PI3Ks 
BEZ235, de forma a compreender se a inativação do FOXO3a tem ou não relação 
com a interação entre o AKT e o TRIB2. Para isso fizeram-se vários estudos para 
não só verificar se há uma co-localização do TRIB2 e do AKT, através de CO-IP e 
de microscopia de fluorescência, bem como para compreender se realmente se 
verifica esta resistência a drogas por parte das células tumorais dos melanoma, e 
se a sobreexpressão de TRIB2 está em concordância um aumento do de AKT no 
seu estado ativo, ou seja fosforilado (pAKT/PO4-AKT) através de estudos in vitro, 
in vivo e ex vivo (com amostras clínicas de pacientes).  
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Atualmente está aprovado apenas um biomarcador para melanoma, LDH. 
Assim, o ideal seria que o TRIB2 fosse igualmente aprovado como biomarcador 
para a doença, para que desta forma fosse possível que através de um “screening” 
a pacientes com melanoma, verificar se há sobreexpressão de TRIB2. Verificando 
ser o caso, evitar-se-ia a administração de inibidores das PI3Ks tal como BEZ235, 
uma vez que esta droga não terá um efeito benéfico para o paciente e este estará 
apenas a sofrer efeitos citotóxicos desnecessários.  
Devem ser feitos mais estudos de forma a elucidar os mecanismos que 
levam a que haja esta resistência, para que se descubram alternativas terapêuticas 
eficazes de forma a melhorar o prognóstico destes pacientes, já que este é dos 
menos promissores para a sobrevivência destes doentes. 
 
Palavras-chave: cancro, melanoma, FOXO3a, PI3K, AKT, TRIB2, BEZ235. 
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1. Introduction 
1.1. Cancer 
The development of organisms involves mechanisms such as proliferation, 
division and growth of cells. The problem arises when the organism is already 
developed and the cells keep proliferating and dividing which in case of wound 
repair is crucial, but when the cells get mutations in their genome, allowing genes 
to acquire new functions, driving the cells to new phenotypes that will no more 
follow their normal process and in the worst case, driving our body to the 
appearance of cancer.1,2  
Unbalance between cell proliferation and apoptosis as well as the 
accumulation of several genetic mutations in DNA are needed for a normal cell to 
become a cancer cell, passing from one mutated cell that goes out of control, to a 
state of neoplasia, when the cancer spreads to other parts of the body.  (Figure 
1.1.1).1,3,4  
 
 
 
  
 
 
 
 
 
 
         
 
 
Figure 1.1.1. Cancer development starts with a single mutated cell and progresses with the 
accumulation of more several mutations followed by changes in gene expression. This genetic 
alterations are represented in different histopathological stages (Hyperplasia, Dysplasia, In situ 
cancer and finally invasive cancer).4 
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Long ago, cancer was a concept to describe just one disease, but nowadays  
incorporates over 100 different diseases, different cancer types wherein  each of 
them consists in a multistage process, consequence of genetic factors like genetic 
mutations or environmental factors that will have an effect in gene expression (i.e., 
drugs, diet, UV).5,6 
For tumor progression, in order to survive and avoid apoptosis, is crucial that 
a cancer cell acquire particular characteristics which are named “The hallmarks of 
cancer”. In 2000, were defined six leading characteristics2, however nowadays with 
the new recent discoveries, are known in total ten (Figure 1.1.2).1  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 Figure 1.1.2: Hallmarks of cancer in 2011 updated from the six named in 2000.1 
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1.1.1. Epidemiology 
Cancer is a worldwide urgent problem since it was responsible for 14.1 
million new cases and 8.2 million deaths in 2012, making cancer one of the most 
deadly diseases in the world whether in non-developed or in developed countries. 
Worldwide most frequent cancers are breast, colorectal and lung cancer. Is 
currently called “the disease of the future” considering one likely 70% increase of 
new cancer cases for the following 2 decades, having 22 million cases instead of 
the 14 million in 2012 due to many factors: the increase of an older population, 
their lifestyle with associated behavioral changes like a sedentary lifestyle, smoking 
and a poor diet.7  
 
1.1.2. Cancer treatment methodologies  
 Cancer treatment is chosen according to the cancer type and stage, 
because each cancer is unique; each cancer will have a different treatment 
approach. People could have just one kind of treatment or a combination of more 
than one, for example surgery (procedure made by a surgeon to remove the tumor 
from your body) is the first approach in case the tumor can be removed, plus 
radiation therapy or chemotherapy in order to kill cancer cells by damaging DNA 
and avoid cells to keep diving.5,8  
1.1.3. Novel cancer therapeutics  
 Optionally, we have also new therapies to address this problem, like 
immunotherapy that is used with the aim of stimulating the immune system  to fight 
cancer, through the activation of immunologic cells (i.e. using dendritic cells 
vaccine).9  
 To avoid tumor progression and induce their regression, targeted therapy is 
another alternative approach which uses drugs to block the action of mutated 
proteins in signaling pathways that are deregulated and that are allowing the tumor 
cells to survive and keep growing.8,10  
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1.2.  Melanoma 
Skin cancer is classified as non-melanoma (basal or squamous cell) or 
melanoma (only 5% of all skin cancer cases), according to the cell type that gave 
rise to cancerous cells. Melanoma arises from the transformation of the 
melanocytes, cells that are located in the bottom of epidermal layer of the skin and 
that are responsible for the production of the pigment melanin. This pigment is 
involved in skin protection mainly against   ultraviolet sun rays exposure, which is 
the major cause of melanocytes transformation. This exposure triggers mutations 
that will lead to an abnormal cell multiplication and consequently to malignant 
tumors formation.11  
Furthermore mutations in CDKN2A and CDK4 genes (involved in cell division 
control) have been shown to be associated with familial malignant melanoma (10-
15% of the cases). However, the most part of the melanoma cases appear 
sporadically, being named sporadic melanoma. Having blue or green eyes and fair 
skin, if the person gets easily sunburns, freckles and moles which (could develop 
to melanoma) are risk factors as well.12,13 
Melanomas can arise from any part of the skin, appearing commonly in the neck 
and face, but preferably on the legs in women and on the chest and back in men.11 
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1.2.1. Epidemiology 
On average, each year 132,000 melanoma are diagnosed cases worldwide. 
Caucasian populations have a higher risk to develop melanoma skin cancer 
comparatively with dark-skinned populations, due to a lower melanin pigmentation 
protection, for these factor Australia population is the one with  highest incidence of 
melanoma since is predominantly Caucasian.14,15 The age more susceptible to the 
appearance of melanoma is the late fifties and are diagnosed more cases in men 
than in women (1.3/1).16  
Melanoma although not the most common skin cancer type, contemplating 
5% of all skin cancer cases,  is the most dangerous one, being responsible for 80% 
of all skin cancer deaths,   making it one of the most aggressive of all human 
cancers. The American Cancer Society (AJCC) predicts that in 2015, there will be 
diagnosed around 73,870 new melanoma cases in the US, showing an increase of 
200% since 1973, wherein 31,200 in women and 42,670 in males, estimating in 
total 9,940 deaths. 5,7,8 
Statistical studies show that New Zealand/Australia has the highest 
melanoma mortality rate in the world with 3.5 deaths per 100 000 habitants, 
followed by the United States of America (USA) with 1.7/100 000 and the third is 
Europe with 1.5 deaths/100 000.7,17 
In Portugal, it was registered in 2007 by the National Cancer Registry, that per 
10.000 habitants we have 6 cases of malignant melanoma, corresponding to an 
increase of 15% since 2001 (with 5.2 cases per 10.000 habitants). Annually, 
appear about 700-800 new cases being the incidence higher in women than in 
men (1/1.14) and the average upper the 50.15,18 
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1.2.2. Stages of disease/diagnosis. 
In order to know how far the cancer is spread, thereby giving a more 
appropriate and accurate treatment, melanoma patients need to have a good 
diagnosis, to consequently have a better prognosis. For that, is used the staging 
system from the AJCC.11 
Prior to melanoma staging, ABCDE nomenclature (Figure 1.2.2.1) is 
performed. This method is used for an early detection and is limited, once the 
asymmetry, border, color, diameter and evolution parameters are self-skin 
checked. If there are abnormal changes, next step is to go see an dermatologist.11  
 
 
 
 
Figure 1.2.2.1: ABCDE system for melanoma diagnosis.11 
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Melanoma staging is usually performed by the American Joint Commission on 
Cancer (AJCC) TNM system, that evaluates the tumor thickness (T), how many 
lymph nodes are affected with cancerous cells (N) and finally if there are any 
metastases, to know how far the cancer spread or not to other organs (M). In 
combination with these factors, are measure as well the tumor ulceration, mitotic 
rate and lactate dehydrogenase levels (LDH). (all described in table 1.2.2.1)19,20  
Nowadays, only LDH is established by the AJCC as a biomarker for 
melanoma prognostic classification system, over more than 60 years ago and is 
used because of their high specificity and sensitivity to detect this disease. A good 
biomarker must obey to some criteria, such as to be measured in an accessible 
body fluid like blood, must be minimally invasive to the patient and to have a low 
cost.20  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 9 of 62 
 
T classification Thickness Ulceration Status/Mitoses 
Tis (In situ) NA (not applicable) NA 
T1 ≤ 1.0 mm 
a: Without ulceration and mitosis < 
1/mm2 
b: With ulceration or mitoses ≥ 1/mm2 
T2 1.01 - 2.0 mm 
a: Without ulceration 
b: With ulceration 
T3 2.01 - 4.0 mm 
a: Without ulceration 
b: With ulceration 
T4 > 4.0 mm 
a: Without ulceration 
b: With ulceration 
N classification Number of metastatic nodes Nodal Metastatic Burden 
N0 0 NA 
N1 1 
a: Micrometastasis* 
b: Macrometastasis** 
N2 2-3 
a: Micrometastasis* 
b: Macrometastasis** 
c: In transit metastases/satellites 
without metastatic nodes 
N3 
4 or more metastatic nodes, or matted 
nodes, or in-transit metastases/satellite 
with metastatic nodes 
 
M Classification Site Serum LDH 
M0 No distant metastases NA 
M1a 
Distant skin, subcutaneous, 
or nodal metastases 
Normal 
M1b 
Lung metastases 
Normal  
M1c All other visceral metastases Normal 
 
Any distant metastases Elevated 
 
Table 1.2.2.1: TNM classification according to the 7th edition of the Melanoma staging system 
by the American Joint Commission on Cancer (AJCC). 20,21 
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To determine  the melanoma patient stage, is made the combination of the 
TNM parameters in order decide the most appropriate treatment according to the 
disease stage (table 1.2.2.2).20  
 
 
Stage 
Melanoma 
Characteristics 
Classification 
5 year survival rate 
T N M 
0 
Carcinoma in situ (in 
epidermis and has not 
spread to dermis) 
Tis N0 
M0 
99 – 100 % 
I 
A/B 
Lesions up to 2 mm but no 
nodal or distant metastases 
T1a N0 M0 
A – 95% 
B –88 - 92 % T1b N0 M0 
T2a N0 M0 
II 
A/B/C 
Lesions greater than 2 mm, 
no positive nodes or distant 
metastases 
T2b N0 M0 
A – 77 - 79 % 
B – 61 - 70% 
C – 43 - 45% 
T3a N0 M0 
T3b N0 M0 
T4a N0 M0 
T4b N0 M0 
III 
A/B/C 
Lesions of any size with 
positive lymph nodes 
Tx N1 M0 
A – 57 – 73 % 
B – 41 – 57 % 
C – 20 – 34 % 
Tx N2 M0 
Tx N3 M0 
IV Lesions of any size with 
distant metastases 
Tx Nx M1 5 – 22 % 
 
Table 1.2.2.2: Melanoma patients staging based in TNM classification according to the 7th 
edition of the Melanoma staging system by the American Joint Commission on Cancer (AJCC) 
plus the measurement of lactate dehydrogenase levels (LDH), tumor ulceration and mitotic rate. 
(Tx-Primary tumor cannot be assessed; NX- Regional lymph nodes cannot be assessed; MX-
Presence of distant metastasis cannot be assessed.) 
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1.2.3. Current treatment options for melanoma. Conventional therapy. 
 Early melanoma detection makes possible that through surgery (surgical 
excision of the tumor and the nearby tissue), most part of primary melanomas 
(about 80%) could be treated and curable. For stage III melanoma patients usually 
have for option one year treatment with adjuvant immunotherapy with interferon-α.  
In advanced stages, with the cancer spreading to other organs, making hard to 
define the best treatment, the prognosis is a real challenge. In these cases, around 
45% of patients with metastatic melanoma receive immunotherapy or 
chemotherapy. For the patients with the worst prognosis, melanoma patients in 
stage IV, surgery is not a viable option, wherein the suggested treatment is 
systemic drug therapy. 16,22–24 
 Conventional chemotherapy uses drugs with aggressive cytotoxic effects, 
mostly alkylating agents, to avoid cell replication. Food and Drug Administration 
(FDA) is the entity that approves these compounds, such as Dacarbazine (DTIC) a 
drug approved in 1975, Fotemustine (Muphoran), Temozolomide (Temodal). The 
problem with these treatments is the fact of just 10% triggers an effective response 
and do not have an overall survival increase. 17,25 FDA recently approved the BRAF 
inhibitor vemurafenib and the MEK inhibitor trametinib for melanoma patients that 
harbor BRAF mutations.26,27 
 Regarding immunotherapy, in 1998 FDA have approved Interleukin-2 (IL-2), 
the first immunotherapy for advanced melanoma, however has the same issue of 
DTIC because even with high-doses of de drug the response is not significant. 
Nowadays, is used in combination with DTIC (since 2011). 28  
Since 2009, new systemic cancer treatments have been emerging wherein 
monoclonal human antibody against the CTL antigen 4 (CTLA-4) commercially 
known as Ipilimumab, was one of the most important discoveries in the research 
for immunotherapeutic drug crucial in immune system stimulation to respond 
against tumor antigens. Recently, was found that Ipilimumab in combination with 
GM-CSF instead Ipilimumab administrated alone is more effective to treat 
metastatic melanoma patients since there is an overall survival increase and lower 
toxicity to the patients.29–33   
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1.2.4. Novel therapeutic approaches useful against melanoma 
Presently, with the aim to provide more quality of life to melanoma patients, it 
is important to search novel therapeutic approaches. Currently, several compounds 
are being tested in clinical trials, including NPV-BEZ235 (BEZ235).34,35.    
For this project, BEZ235 (Novartis) was our particular research focus. BEZ235 
is a selective PI3K and mTOR dual inhibitor, classified as an imidazoquinoline and 
tested already in many clinical trials that have showed anti-cancerous properties, 
such as the induction of apoptose, suppression of cell proliferation, induction of G1 
cell cycle arrest and inhibiting the function of many proteins such as AKT, S6, S6K. 
This drug is given orally to the patients, having side effects like nausea, headache 
diarrhea, with a stable response demonstrated in clinical trials.36–40 
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1.3. PI3K/AKT pathway 
PI3K/AKT signaling pathway (showed in Figure 1.3.1) has been a crucial 
target for research not only because it is involved in many regulatory cell 
mechanisms (differentiation, migration, growth, proliferation and survival)41,42 , but 
also for being one of the most mutated pathways in human cancers.43 
Phosphoinositide 3-kinase (PI3K) is a lipid kinase. It is a heterodimer since it 
is constituted of two subunits: catalytic (p100) and regulatory (p85). 40,44 PI3K is 
one of the most important component in this pathway, having a central role in the  
regulation of angiogenesis  (formation of new blood vessels), apoptosis 
(programmed cell death), cellular metabolism, and Deoxyribonucleic acid (DNA) 
repair.45,46    
PI3K activation could be made through many signals, such as the interaction 
between transmembrane tyrosine kinase-linked receptors (RTKs), G-protein 
coupled receptor (GPCR), or simply by cell-to-cell interaction.47 This activation will 
trigger the phosphorylation of PI3K substrate phosphatidylinositol-4,5- 
bisphosphate (PIP2, present in the cellular membrane) into phosphatidylinositol- 
3,4,5- triphosphate (PIP3), a fast action that takes just seconds.42,45,47 After this 
conversion, PIP3 will recruit to the cell membrane proteins that contain a pleckstrin 
homology (PH) domain, like the protein kinase B (PKB or more known as AKT). 
AKT named as the first downstream mediator of PI3K signaling pathway, belongs 
to serine-threonine kinase family, and in mammals exists in three isoforms (AKT1/ 
AKT2/AKT3) encoded by three different genes, been expressed in variable levels, 
according to the tissue in question.48 In order to achieve total activity, AKT must 
have both their conserved residues (threonine 308 and serine 473) 
phosphorylated, being threonine 308 residue targeted by the kinase 
phosphoinositide-dependent kinase 1 (PDK1) and serine 473 residue by 
Mechanistic Target of Rapamycin Complex 2 (mTORC2). At this moment, p-AKT is 
ready to phosphorylate other downstream substrates that are involved in cell 
regulation. One negative regulator of this pathway is PTEN (tumour suppressor), 
that will through their  phosphatase function, dephosphorylate PIP3 into PIP2 
avoiding that AKT becomes activated.40,45  
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Figure 1.3.1: Regulators, effectors, and somatic alterations in the PI3K–AKT pathway in 
melanoma.40 
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1.3.1. The role of the PI3K network in Melanoma 
PI3K/AKT signaling pathway in our particular field of research, is deregulated 
in a high proportion of melanomas, so by understanding how the molecules of this 
pathway intact and the mechanisms involved, will make possible the discovery of 
molecules in order to avoid  melanoma progression. 43,44,46 
In Melanoma cells, AKT3 isoform has a higher expression than AKT1 and 
AKT2, since their activation is identified in about 60% of sporadic Melanomas.26,49  
AKT promotes a perfect environment to these cancerous cells, since it allows these 
cells to avoid apoptosis, to keep growing, proliferating, to resist to hypoxia (low 
levels of oxygen in the cells/tissues) and increasing cell metabolism, due to the fact 
of AKT is constitutively active. When AKT is activated it translocates from cell 
membrane to the cytoplasm (figure 1.3.1.1) and then to different cell places to 
target substrates.47,50,51 
 
 
Figure 1.3.1.1: AKT activation through PDK1 and mTORC2 phosphorylation.46 
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1.3.2. Forkhead transcription factors  
As mentioned previously, many effector proteins and substrates are 
phosphorylated by pAKT (active form of AKT) and Forkhead box O3a (FOXO3a) is 
one of them. FOXO3a is a member of the family FOXO which is a subgroup of 
Forkhead transcription factor family.52 FOXO3a is a transcriptional factor located 
and active in the nucleus, responsible for the regulation of the expression of genes 
that are involved in many mechanisms such as Cyclin-dependent kinase inhibitor 
p27 (p27), a cell cycle inhibitor; Fas ligand (FasL), a ligand responsible for Fas-
dependent cell-death; Bcl-2 Like protein 11 (Bcl-2L11, also known as BIM), a Bcl-2 
family member (which possess conserved Bcl-2 homology [BH] domains 34) 
responsible for pro-apoptotic signaling.53  
FOXO3a is negatively regulated by AKT phosphorylation, leading FOXO3a to 
translocate from the nucleus to cytoplasm, becoming inactive and consequently 
represses transcription anti-apoptotic genes. In the cytoplasm FOXO3a will be 
polyubiquitinated and marked for proteosomal destruction (Figure 1.3.2.1).53 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
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Figure 1.3.2.1: A) FOXO active in the nucleus, transcribing genes involved in cell cycle arrest and 
apoptosis ( p27, FasL and Bim); B) FOXO regulation through AKT leads to their exportation from 
the nucleous to the cytoplasm.  
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1.4. Tribble2 homolog.  
Being LDH the only biomarker approved by FDA for melanoma, there is a 
need to find new melanoma biomarkers and actually many are been tested in 
clinical trials, such as  S-100 calcium binding protein B (S100B); tyrosinase (TYR);  
human pituitary tumour-transforming gene 1(hPTTG1); RGS1 (Regulator of G-
protein signaling 1);  heat shock protein 90 (HSP90); Secreted phosphoprotein-1 
(SPP1); Inhibitor of growth family 3 (ING3); Nuclear receptor coactivator-3 
(NCOA3). 54–60 
In addition to the discovery of these biomarkers, it was discovered Tribbles2 
(TRIB2) correlates with melanoma. TRIB2 is the mammalian homolog of the 
drosophila gene tribbles2 (was described firstly in this specie). In drosophila, this 
protein is involved in cell cycle control during morphogenesis and oogenesis, being 
involved as well as in regulation of cell proliferation, metabolism, motility and 
cancer development.52 
TRIB2 is a kinase-like protein or a pseudokinase as it belongs to the TRIB 
pseudokinases family, composed for three members (TRIB1/TRIB2/TRIB3) whose 
catalytic residuesare not conserved, conditioning their catalytic function. 
Structurally, is divided in three distinct regions: N-terminal region, a serine-
threonine kinase-like domain (KD, that has evident homology with serine-threonine 
kinases) and a C-terminal domain, a binding site for E3 ubiquitin ligases (Figure 
1.4.1.).52  
Figure 1.4.1: TRIB2 domains: N-terminal, kinase domain and C-terminal (two binding motifs, 
one for MEK1 and one for COP1). 
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The three TRIB members are all related with human cancers, having roles in 
signaling pathways such as MAPK and PI3K/AKT, interacting with many 
transcription factors and signaling molecules: MAPKK, ATF4, p65, COP1, CtIP, 
and AKT, being implicated in regulation of gene expression, apoptosis, cell 
activation and mitosis.52,61,62 
TRIB2 is known to be overexpressed in human malignant melanoma and it is 
related with FOXO3a export from the nucleus to the cytoplasm, leading to the 
inhibition of FOXO3a tumor suppressor function. Although it is not known exactly 
how this mechanism works, it is believed that TRIB2 is a good research target to 
avoid melanoma cells growth and increase patients overall survival since is 
implicated in the maintenance of melanoma cells properties. 22,52  
TRIB2 is is involved in cell division and has been reported to be up-regulated 
in a subset of acute myeloid leukemia’s and members of tribbles family have been 
also reported to interact and modulate the activity of signal transduction pathways, 
including the PI3K/AKT and the MAPK, our pathways of interest. It is important to 
say that TRIB2 has been implicated in the negative regulation of FOXO3a and this 
knowledge is important to understand the mechanism(s) of action of how TRIB2 
mediates PI3K inhibitor resistance and the role of FOXO3a in this response. Thus, 
if we knew how this pathway works and their mechanisms are related to tumor 
progression and melanomas appearance, we could design strategies to treat 
cancer in earlier stages through target therapy.35,61–63      
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1.5. Hypothesis 
It is known that PI3K/AKT is one of the most mutated pathways in human 
cancer, is also known that FOXO mediates the action of many anticancer drugs 
and that TRIB2 negatively regulates FOXO. Our research group has demonstrated 
that TRIB2 is not only a biomarker for melanoma diagnosis, but is also involved in 
this cancer type progression being our biggest aim to understand how is TRIB2 
allowing melanoma patients to acquire  resistance to chemotherapeutic drugs, in 
particular to PI3K inhibitors, like BEZ235. Through in vivo models with an oral 
administration to be a representative model to the patients in the clinic, and ex vivo 
samples from melanoma patients to see if there is a drug resistance caused by 
TRIB2 and knowing that AKT negatively regulates FOXO, to understand this 
mechanism of resistance, was hypothesized if does this happen because TRIB2 is 
in AKT network and if they interact. Since preliminary results from our group 
indicate that TRIB2 confers chemotherapeutic resistance, the central aim is to 
elucidate the mechanism(s) of this resistance and in particular how the TRIB2 
protein responds following PI3K inhibition. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2.  Materials and Methods 
2.1. In vitro studies 
2.1.1. Cell culture 
 For this project were used isogenic cell lines, SK-MEL-28  derived from a 
range of melanoma cell lines settled from skin primary tumor samples from a 51-
year-old male patient (unknown ethnicity), acquired from American Type Culture 
collection (ATCC) and SK-MEL-28  TRIB2 shRNA; G-361 also acquired from 
ATCC was established from a malignant melanoma of a 31 year old male 
Caucasian. U2OS cell line (Human Bone Osteosarcoma Epithelial Cells) derived 
from a fifteen-year-old human female suffering from osteosarcoma; 293T shrna 
TRIB2 cell line originated from human renal cancer cells. All cell lines were 
defrosted from -80ºC and cultured within 35mm plates in 3ml DMEM (Dulbecco's 
Modified Eagle Medium Sigma, USA) medium with 10% heat inactivated FCS 
(Sigma) supplemented with Pen/Strep (Gibco) to be used for BEZ235 (10nM) drug 
treatment whereby were added 3ul of the drug to get a 1:1000 ratio. After the drug 
addition, all the cell cultures were kept overnight in a humidified incubator in 5% 
CO2 at 37ºC.First of all, the medium was aspirated and to detach the cells from the 
culture plates was used 1ml of Trypsin-EDTA 1x solution (SAFC Biosciences, UK). 
After trypsinization, the trypsin with cells was transferred to a falcon to centrifuge at 
11rpm during 5 minutes.  
The pellet was washed with 800ul of Phosphate buffered saline (PBS) 1x and 
shifted to an eppendorf for protein extraction.  
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2.1.2. Transfection 
We used JetPrime transfection Protocol to transfect our cell lines with a 
dilution of 2 μg of our DNA into 200 μl jetPRIME® buffer, both posteriorly mixed by 
vortexing. After, was added 4 μl of jetPRIME®, vortexed for 10 seconds and then 
spun down briefly. 10 minutes room temperature incubation and thereafter it was 
added 200 μl transfection mix per plate. Lastly, the plates were slowly shaken and 
placed into the humidified incubator in 5% CO2 at 37ºC for 24h. 
 
2.1.3. Protein fragment complementation assays (PCA) 
5 μg of our each plasmid construct (ZIPV1, ZIPV2, AKT1, AKT2, TRIB2, 
TRIB3 or JIP1) were transfected (JetPRIME following the manufacturers protocol) 
into 293 cells. 24 hours post transfection, cells were stained for YFP imaging and 
visualized on a Leica TCS SP5 II confocal microscope. Duplicate studies were 
conducted and fluorescent signal intensity was measured 24 hours post dual 
construct transfection using a BD FACS Calibur scanner. The leucine zipper 
constructs ZIPV1 and ZIPV2 serve as positive control for these studies. 
 
2.1.4. Co-Imunnoprecipitation (Co-IP) 
After protein sample quantification using the Bradford assay followed by 
Nanodrop measure, were added PBS up to 500ul depending of the protein value to 
be loaded, plus 5ul of primary antibody and stayed overnight in the rotator at 4ºC. 
For each sample were needed 20ul of protein A/G-agarose beads (Sigma) which 
were first washed 2x with PBS. 1300 spin for 2min and only keep the pellet to be 
mixed with 20ul of PBS and the resuspended. Spin 1300 rpm for 2min and waste 
the PBS. Were added 20ul of beads to each sample, then resuspended and placed 
1h on the rotator. Another 1300 rpm spin for 1min and after that were made one 
wash with 200ul of PBS. Spin 1300rpm 1min. Once again the pellet was kept and 
were added 40ul of laemmli, boiled for 5min at 98ºC and 20ul of each sample were 
used to be loaded in SDS-PAGE gel. 
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2.1.5. Immunofluorescence 
In order to have samples to see in the Microscope, we need to prepare them 
previously after cell growing in the desired conditions (Table 2.4.1.1). First of all we 
put each lamella with respective cell line condition in a six well plate with PBS 
solution (10x). 
 
  
Table 2.4.1.1: Cell lines for Immunofluorescence. 
 
Then, we transferred the lamellas with the cells side face up to a new six well 
plate wash 3x with PBS (1x) and after that see in the Microscope if there is a good 
cell confluence. If the cells look fine, we could proceed with the dual staining 
protocol. We cover a western blot glass with parafilm paper and put four equal 
drops (more or less 200ul) of 1:30 block solution (900ul PBS (1x) + 30ul block 
solution (stock))and after that lay down the lamellas with the cells side face down 
to be in contact with the solution, one per drop. Incubate in the Humified Chamber 
for 1h, 37ºC. (Cell culture incubater). We took  the lamellas from the Humified 
Chamber and put them with the cells face up in the parafilm paper, cleaned the 
block solution from the glass with parafilm and prepared 1:500 1ºAB for 1ul p-AKT 
(Santa Cruz) and 1ul TRIB2 (Santa Cruz) in PBS (1x) and put four drops of that 
mix in the glass with parafilm. Then, put the lamellas face down in contact with the 
1ºAB and incubate  in the Humified Chamber for 1h, 37ºC.   
 
Cell lines for Immunofluorescence 
293T Skmel-28 
293T EMPTY NT Skmel-28 EMPTY NT 
293T EMPTY BEZ Skmel-28  EMPTY BEZ 
239T TRIB2 NT Skmel-28   TRIB2 NT 
293T TRIB2 BEZ Skmel-28    TRIB2 BEZ 
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Took lamellas from the Humified Chamber and put them with the cells face up 
in the six plate wells and wash them 3x with PBS (1x). Clean the 1ºAB from the 
glass with parafilm. We prepared 1:500 2ºAB for 1ul α-mouse (against TRIB2) (1ul) 
and 1ul α-rabbit (against p-AKT) in PBS (1x) and put four drops of that mix in the 
glass with parafilm. Then, put the lamellas face down in contact with the 2ºAB. 
Incubate in the Humified Chamber for 1h, 37ºC.  Took lamellas from the Humified 
Chamber and put them with the cells face up in the six plate wells and wash them 
3x with PBS (1x). Clean the 2ºAB from the glass with parafilm. For each 
condition/lamella, one lamina where was placed one drop of ClearMount™ 
Mounting Solution, INVITROGENTM. Then we put the cells face down and incubate 
in a 60ºC chamber for 30 minutes. After the 30 minutes, we've saved them there in 
the dark, very important to not leave them in the light! The Microscope used for 
image visualization were Axio Imagen Z2. 
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2.2. In vivo studies 
2.2.1. BEZ235 treatment of Xenografted mice. 
This work was performed with 21 animals (table 2.2.1.1), which were divided 
into two initial groups to be injected with different isogenic cell lines, in order to 
form tumors: 14 mice injected with 2x106 293T-empty cells into the right flank of 
matched NOD/SCID mice and at the same time, the other 7 were injected with 
2x106 293T-TRIB2 cells into the right flank of matched NOD/SCID mice. These 
animals were monitored daily for tumour development, and once tumors were 
visible, they were measured prior to in vivo treatment. The 14 mice containing 
293T-empty tumors were then separated into two groups of 7 mice prior to the 
BEZ235 in vivo study commencing, having after one group with endogenous levels 
of TRIB2 and no drug treatment, 293T Empty Vehicle (n=7); other group with 
endogenous levels of TRIB2 and BEZ235 drug treatment, 293T Empty BEZ235 
(n=7) and finally the last group with overexpression of TRIB2 plus BEZ235 drug 
treatment, 293T TRIB2 BEZ235 (n=7). Drug aliquots were prepared for one or two 
days (since the compound is stable for only two days),  being the average mice 
weight 25g, and the concentration to be administrated to the mice 30mg/Kg, the 
calculation is 10,5mg of BEZ235 dissolved in 2,1ml of 20% NMP/80% PEG 300 for 
one day.  This compound must be protected from the light and be stored at 4ºC, 
the NMP is added to BEZ235 and  must stir for 30 min at 40ºC (protected from 
light), PEG300 as well must stir but for 60 min at 40ºC (protected from light) and 
then keep at RT to be used in the drug  administration. 
The animals had a daily tumor measurement and daily drug treatment with 
BEZ235: 30mg/kg, orally administrated (syringes provided by Prof. Inês Araújo)  
but with the mice anaesthetized/sedated with isoflurane (Cell line injection to the 
mice, tumour measures, and drug administration was made by Dra. Patrícia 
Madureira). 
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Table 2.2.1.1. Xenografted mice groups. 
 
 In the end of the study, the animals were sacrificed after been exposed with 
CO2 (by Dr. Richard Hill), and the organs (spleen and tumors) were surgically 
removed (by Dra. Patrícia Madureira) for protein and RNA extraction. 
 
2.2.2. Western Blotting 
We’ve collected the following organs for protein extraction and 
quantification: the liver, the spleen and the tumors. The organs homogenization 
was made in a manual potter homogenizer (Sigma) with 200ul-500ul (depending 
on the organ size) of RIPA Buffer (Tris-HCL ph 7.4, NaCl, 10% Nonidet P-40, 10% 
sodium deoxycholate, 100 mM EDTA, PIC, 200 mM NA-F, 100mM Na3VO4 and 
protease inhibitors cocktail) for the tumors and livers or 300ul for the spleens. 
Then, the homogeneized samples incubated for 30 minutes on ice. The lysed 
samples were spun at 13000 rpm and the supernatant transferred to a new 
eppendorf for posterior protein quantification. Extracted proteins were stored at -
80ºC until use. For protein quantification to determine their concentrations we used 
the BCA assay (Thermus Scientific Protein Assay Kit). Then, to be quantified we 
used 2ul of that mix to be read in the NanoDrop 2000/2000c (ThermoScientific) 
UV-Vis Spectrophotometer.  
 
 
 
Xenografted mice (n = 21) 
Groups Number of animals Number of injected cells 
293T Empty Vehicle n=7 2x106 
293T Empty BEZ235 n=7 2x106 
293T TRIB2 BEZ235 n=7 2x106 
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Our extracted protein samples were diluted into 2x lammeli loading buffer 
(containing β-mercaptoethanol) and heat for 5 minutes at 95ºC to be loaded into 
10% SDS-PAGE gels with the NZYBlue Protein marker. Once the proteins were 
separated, the gel was transferred to a nitrocellulose membrane (Amersham 
Hybond ECL) Nitrocellulose Membrane through TRANS-BLOT® SEMI-DRY 
TRANFER CELL (BioRad) system for 1h10min. The membranes were blocked with 
skimmed milk powder (exception when we used p-MDM2 Antibody, in which case 
BSA was used) and placed on a shaker for 1 hour to prevent the binding of non-
specific antibodies and probed with many primary antibodies (table 2.2.2.1) 
overnight at 4ºC. 
 
 
 
Table 2.2.2.1: Primary antibodies. 
 
 
 
Primary antibodies Supplementary information 
  Total AKT C-20; sc-1618; Goat; Santa Cruz Biotechnology 
p-AKT Ser 473; sc-7985; Rabbit; Santa Cruz Biotechnology 
Actin I-19; sc-1616; Goat; Santa Cruz Biotechnology 
p53 DO-1; sc-126; Mouse; Santa Cruz Biotechnology 
Total MDM2 C-18; sc-812; Rabbit;Santa Cruz Biotechnology 
p-MDM2 S166; 3521S; Rabbit; Cell Signalling Technology 
TRIB2 Custom, Rabbit, CNIO Madrid 
Total FOXO N-16; sc-9813; Goat; Santa Cruz Biotechnology 
p-FOXO Ser253; sc-101683; Rabbit; Santa Cruz Biotechnology 
BIM H-191; sc-11425; Rabbit; Santa Cruz Biotechnology 
p21  C-19; sc-817; Mouse; Santa Cruz Biotechnology 
p70 S6 Kinase α C-18;  sc-230; Goat; Santa Cruz Biotechnology 
Fas-L C-178; sc-6237; Rabbit; Santa Cruz Biotechnology 
Cleaved Caspase-3 h176; sc-22171; Rabbit; Santa Cruz Biotechnology 
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After incubation, were washed for 10 minutes with TBS 0.1% tween20 (3x) 
and then, probed it with matched secondary antibodies for 1 hour at room 
temperature in the shaker.  
 
  
   Table 2.2.2.1: Secondary antibodies. 
 
Membranes were once again washed for 10 minutes with TBS 0.1% tween20  
(3x) and  perform an image visualization, the membranes were placed in a ECL 
solution which is a mix of a Buffer 1 (5ml 1M Tris pH 8.5 100nM, 0.5ml luminol 
2.5nM, 222.3ul p-coumaric-acid 360uM, 45.5ml H2O) and Buffer 2 (4ml 1M Tris pH 
8.5 100nM, 46ml H2O, 31ul 30% H2O2)  and then achieved through a Molecular 
Imager® ChemiDoc™ XRS System (BioRad). 
 
 
 
 
 
 
 
Secondary 
Antibodies 
Secondary Antibodies 
Anti-mouse IgG-HRP; sc-2314; Donkey; Santa Cruz Biotechnology 
Anti-rabbit  IgG-HRP; sc-2004; Goat; Santa Cruz Biotechnology 
Anti-goat IgG-HRP; sc-2020; Donkey; Santa Cruz Biotechnology 
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2.2.3. RNA Extraction/cDNA Synthesis  
 RNA extraction and isolation was made from the tissue samples of the 
animals and to each were added 500ul of TRI Reagent® (Sigma). After 5 minutes 
of room temperature incubation, was added 100ul of chloroform for each sample 
and we’ve mixed them manually up and down and then centrifuged at 12000xg for 
15 min at 4ºC, resulting in 3 visually and distinct phases: in the bottom of the 
Eppendorf the organic phase which contains protein, the interphase with the DNA 
and finally our phase of interest in the top, containing RNA, the aqueous phase. 
We just collected the aqueous phase, without taking any interphase to avoid 
contamination with DNA, transferred to a fresh Eppendorf adding 250ul of 
isopropanol to each sample, incubated for 10 minutes at room temperature, and 
centrifuged at 12000xg for 10 minutes at 4ºC, obtaining a white pellet of RNA. The 
supernatant was discarded and the pellet washed with 500ul of 75% ethanol. Next 
step was a centrifugation at 7500xg for 5 minutes at 4ºC, thereon the ethanol was 
discarded and the pellets air dry around 5 minutes. Finally we ressuspended the 
RNA pellets in RNase-free water (DEPC-treated water) aiming to be used for 
cDNA synthesis. To obtain cDNA we used NZY First-strand cDNA Synthesis Kit 
(NZYTech, Portugal), wherein the protocol is described the following steps: on ice, 
add for each sample 10ul NZYRT 2x MasterMix, 2ul EnzymeMix, 6ul of DEPC-
treated water and 2ul of RNA. After slightly mixed, were used the BioRad C1000 
Therm machine with the Programe BioRad manager where the samples incubated 
for 10 minutes at 25ºC and then at 50ºC for 30 minutes. It was made the 
inactivation of the synthesis reaction through samples heating at 85ºC for 5 
minutes and then placed on ice to add 1ul of NZY RNAse H (E.coli) for the last 
step at 37ºC for 20 minutes. 
 
 
 
 
 
 
Page 31 of 62 
 
2.2.4. Statistical studies with two-tailed ANOVA analysis 
ANOVA analysis could be either one-way/one-tailed if we want to evaluate 
just one categorical factor, or could be made a two-way/two tailed analysis if we 
want to evaluate two categorical factors. 
Statistical analysis were done using two-tailed ANOVA analysis, once the goal 
were to see if there was a significant difference in the weight and length of the 
spleens among the different animals groups (293T Empty Vehicle, 293T Empty 
BEZ235, 293T TRIB2 BEZ235) and if that could be related to the drug treatment. 
For that, graphs were made based on the average of the values obtained with the 
spleens measures. Statistical analysis results were treated using unpaired two-
tailed student t-test (Graph pad PRISM). The P value generated for each 
comparison is used to show if the results are or not significant.   The symbols used 
in order to see if there is or not a significant difference, were based in the following 
values: * P≤0.05; ** P≤0.01; *** P≤0.001; **** P≤ 0.0001. When P≥0,05 there is no 
significant difference, where N/S is indicated and in this case P value is not 
significant. For example, if the value is P ≤ 0,01, the result is more statically 
significant comparatively with a P≤0.05.  
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2.3. Ex Vivo: Patient Tissue Samples 
Dr Selma Ugurel (Julius-Maximilians- Universität Würzburg, Germany) 
provided to our group normal and melanoma tissue samples (represented in the 
table 2.3.1) being cryo-preserved until processing. These samples were sectioned 
for Immunohistochemistry (at Faro Hospital) and part of the tissue was used for 
protein and RNA analysis using TRI-Reagent (Sigma). This tissue samples were 
surgically excised prior to first-line treatment from patients with stage IV metastatic 
lesions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 Table 2.3.1: Melanoma and Normal tissue samples used in this work. 
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RESULTS 
  
Page 34 of 62 
 
3. Results 
3.1. Increased TRIB2 protein expression confers significant resistance 
to PI3K/mTORC1 inhibitors in vivo. 
Previous data from our group (published and unpublished) indicated that 
TRIB2 is a negative regulator of the forkhead transcription factor FOXO3a.52 As a 
critical cellular protein that mediates the transcription of several pro-apoptotic and 
cell cycle arrest genes, we hypothesized that TRIB2 could confer resistance to 
many standard front line chemotherapeutics as well as a number of novel PI3K 
inhibitors, including BEZ235. A large in vitro screen using isogenic cell lines 
generated within our group confirmed this hypothesis. Critically, it was unknown if 
high TRIB2 expression could confer resistance to the PI3K/mTORC1 inhibitor 
BEZ235 in vivo. This is a crucial as patient tumors do not present as a flat 
monolayer and rather, are large, tumour masses that contain leaky blood 
vasculature, hypoxic regions and are in general, highly inaccessible for direct 
exposure to these therapeutics. 
To address this question, we first grew low passage isogenic 293T cells with 
stable TRIB2 over expression. Using an immunoblotting approach, we confirmed 
that our cell lines had matched TRIB2 protein expression (Figure 3.1.1). We 
collected and ran 100 μg of total cell lysate (RIPA lysis buffer) on a 10% SDS-
PAGE gel.  
This immunoblot analysis also confirmed that our shRNA constructs against 
TRIB2 were effective (although opted against using these in our in vivo study) and 
rather, for our in vivo studies, compared the endogenous 293-GFP and 293T-
TRIB2 cell lines. 
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Figure 3.1.1: Representative immunoblot analysis of TRIB2 status in our 293T isogenic cell lines. 
Stable scramble shRNA sequences sc.) in the lanes indicated with no knock down of target. Our 
two shRNA constructs (#1 and #2) knock TRIB2 down over 90%. β-Actin is used as a 
loading control for immunoblot analysis.  
 
 
Having confirmed the status of our 293T cell lines, we questioned if 1), TRIB2 
status affected the rate of in vivo tumour growth and 2). If TRIB2 status correlated 
with in vivo tumour response following BEZ235 treatment. To address question 1, 
we injected 2x106 293T-TRIB2 cells into the right flank of 7 age and sex matched 
NOD/SCID mice. At the same time we injected 2x106 293T-empty cells into the 
right flank of 14 matched NOD/SCID mice. These mice were monitored daily for 
tumour development. Once tumors were noted they were measured prior to in vivo 
treatment. The 14 mice containing 293T-empty tumors were separated into two 
groups of 7 mice prior to the BEZ235 in vivo study commencing.  
 
 
 
Page 36 of 62 
 
Palpable tumors were present in each mouse (100% tumour take) and at the 
time the study as initiated, there was no difference between any of the test groups 
(Figure 3.1.2, time post-treatment day 1). When the average tumour volumes were 
calculated at day 1 and the averages compared, we note a P value of 0.915 
indicating that there is no significant difference at all between the in vivo tumour 
growth rates prior to BEZ235 treatment. Strikingly, we note that following the daily 
oral administration of BEZ235, 293T-empty cells start to show reduced tumour 
burden as early as day 5 post-treatment.  
In contrast, 293T-TRIB2 tumour bearing mice treated with an identical dose of 
BEZ235 (30mg/kg) do not display any delay or change in tumour growth. The 
293T-TRIB2 growth plot was very similar to the profile noted for the 293T-empty-
vehicle only treatment group.  
At the completion of the in vivo study, we noted that there was a highly 
significant difference between the treated 293T-empty BEZ235 treated group 
versus the matched 293T-TRIB2 BEZ235 treated group (P value = 0.0299) and the 
293T-Empty BEZ235 treated group versus the 293T-empty vehicle treatment only 
group (P value = 0.0062) (Figure 3.1.2).  
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Figure 3.1.2. TRIB2 conferred resistance to PI3K inhibitors in vivo. TRIB2 overexpressing 293T 
tumors (n = 7) show little to no response to daily administration of BEZ235 compared to isogenic 
lines with endogenous (low, n =7) TRIB2 expression. (Tumors measures done by Dra. Patrícia 
Madureira) 
 
 
In contrast, the 293T-TRIB2 BEZ235 treated group versus the 293T-empty 
vehicle only treatment, had no statistically significant difference (P value = 0.6459). 
From this study, we can conclude that BEZ235 treatment drives significant tumour 
reduction only in 293T tumors with endogenous (low) TRIB2 expression. When 
TRIB2 protein level is significantly increased, there is little to no effect following 
daily BEZ235 administration.  
Based on this data, we questioned if the significantly reduced tumour 
burden correlated with an equivalent difference in survival. From this study, 
Kaplan-Meier survival plots were generated and each treatment group was 
evaluated (Figure 3.1.3). 
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Figure 3.1.3. Elevated TRIB2 expression significantly reduced the survival of 293T tumour bearing 
mice. Kaplan-Meier analysis of isogenic TRIB2 cell lines grow subcutaneously in NOD/Scid mice 
treated with vehicle (n = 7), or BEZ235 (n = 7). The presence of TRIB2 significantly reduced survival 
(log rank P = 0.033) when treated daily with BEZ235.  
 
As we would have predicted based on our in vivo tumour measurement data, 
we note that there is a highly significant difference in overall survival. The 293T-
empty treated mice compared to 293T-TRIB2 BEZ235 treated mice show a highly 
significant survival difference (P value = 0.0339) and when the 293T-empty 
BEZ235 group is compared to the 293T-empty vehicle only group, this difference is 
even more pronounced (P = 0.0083). In contrast, when the 293T-TRIB2 BEZ235 
group is compared to the 293T-empty vehicle only group, there is no statistically 
significant difference (P = 0.6374). Based on these findings, we conclude that the 
over expression of TRIB2 significantly reduces the effectiveness of BEZ235 
following daily oral administration. This was not related to the delivery agent at all 
(as 293T-empty vehicle only treated tumors grew at the same rate as the 293T-
TRIB2 BEZ235 treated tumors) and was not a result of the oral treatment 
procedure itself as every mouse underwent the same procedure (including volume 
of drug/vehicle directly administered).  
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3.2. In vitro cell characteristics are retained in our in vivo model. 
Having noted that high TRIB2 expression significantly increased in vivo 
resistance to daily BEZ235 treatment, we questioned if the in vitro differences 
between our isogenic cell lines were retained within the 3-dimensional architecture 
of a solid tumour. As each mouse was sacrificed (either due to tumour burden or 
the study being concluded [as established in our ethics documentation]) we 
surgically extracted the tumour (if present) and examined all of the internal organs 
(discussed in 4.3). 
Tumors were extracted from the mice in each group and from this we 
extracted RNA (TRI-Reagent, SIGMA) and total protein (RIPA lysis buffer) as 
described in materials and methods. Following the extraction of the total protein, 
we conducted immunoblot analysis (Figure 3.2.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.1: Representative immunoblot analysis from in vivo treated/mock treated isogenic 293T-
Empty/TRIB2 tumors. Individual tumors are labelled (1-5), X indicates that the mouse was alive at 
the end of the study however there was no detectable tumour. 50-150 μg total protein lysate was 
loaded per lane (depending on target protein). β-Actin is used as a loading control for 
immunoblot analysis.  
Page 40 of 62 
 
We note that there was a significant difference in the level of activated AKT, 
specifically pSer473-AKT within the 293T-TRIB2 BEZ235 treated tumors compared 
to the 293T-empty BEZ235 treated tumors. This was also observed for total AKT 
where 293T-TRIB2 tumors had extremely high levels of this protein compared to 
either 293T-empty BEZ235 or 293T-empty vehicle only treatment groups.  
Consistent with this observation we note that BEZ235 treated 293T-TRIB2 
tumors show higher pThr389 p70S6K compared to BEZ235 treated 293T-empty 
tumors and interestingly, 293T-empty vehicle only treated tumors retained very 
high levels of pThr389 p70S6K and pSer473-AKT compared to the 293T-empty 
cells treated with BEZ235 indicating that this drug was reaching the tumors and 
inhibiting PI3K/mTORC. We examined the downstream signalling of the PI3K 
pathway and evaluated the expression of the known AKT target FOXO3a. We were 
unsuccessful in our immunoblotting attempts to visualize total FOXO3a however, 
we did detect the critical pSer253-FOXO3a. In 293T-empty BEZ235 treated 
tumors, we see a significantly lower level of pSer253-FOXO3a compared to either 
293T-TRIB2 BEZ235 or 293T-empty vehicle only treated tumors suggesting again 
that in 293T-empty BEZ235 tumors, there is significant inhibition of PI3K/mTORC 
signalling.  
Next we questioned if there was a difference regarding FOXO3a-dependent 
target gene expression. As the pro-apoptotic FasLG is regulated by FOXO3a, we 
investigated the protein level of FasLG. Interestingly, our immunoblot analysis 
showed that in general there was little difference between any of our treatment 
groups. This does not exclude the possibility that while the total level of FasLG was 
similar, that the activity of this death receptor was the same (this is currently under 
investigation in the laboratory). A critical aspect to consider is that in the 293T-
empty BEZ235 treated mice, there was a number of mice that displayed complete 
tumour regression (indicated in the blots as X where no protein could be loaded). 
Our in vitro studies indicated that TRIB2 could confer resistance by significantly 
reducing the percentage of Sub-G1 cells following BEZ235 exposure (currently 
under review). Based on this data, we questioned if, in vivo, there was a difference 
in a critical apoptosis marker, cleaved caspase3.  
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We note that in both BEZ235 treatment groups, irrespective of TRIB2 status, 
that there was significant cleavage of caspase3 that was not detectable in 293T-
empty vehicle only treated tumors. Interestingly, there seems to be more caspase3 
cleavage in 293T-TRIB2 BEZ235 treated tumors, however one must consider a 
number of caveats from this observation.  
First, the actual tumour mass for each tumour was significantly higher in the 
293T-TRIB2 BEZ235 group suggesting that while there is apoptosis occurring, it is 
insufficient within this background (high TRIB2) to mediate sufficient tumour 
destruction. In contrast, within the 293T-empty genetic background, the level of 
apoptosis is sufficient to drive potent tumour-reduction. 
We also evaluated the protein expression of the tumour suppressor p53 and 
note that in 293T-TRIB2 BEZ treated tumors that there was a very high level of 
total p53 compared to either 293T-empty vehicle treated tumors or 293T-empty 
BEZ235 treated tumors. A possible reason for this could be that the large tumour 
mass is generating large hypoxic regions where p53 can accumulate while there is 
also clearly detectable apoptosis and this is capable of activating p53, driving more 
apoptosis in a feedback-loop.64 
Our immunoblot data indicates that after the oral administration of BEZ235, 
the drug was reaching both 293T-empty and 293T-TRIB2 tumour. However 
BEZ235 was only mediating an effect in 293T-empty tumors. This raised the 
question as to whether there was any noted side-effects following treatment in the 
tumour bearing mice or if any non-tumour organs were effected post-BEZ235 
treatment. When the tumors were excised, we carefully examined all the organs 
within the mice. We noted no adverse effect in the oesophagus, stomach, liver, 
heart, lung or kidneys of BEZ235 treated mice (data not shown). Strikingly, we 
noted a highly adverse effect on the spleen in treated mice. We carefully excised 
the spleens (at the same time we removed the tumour) and measured them 
(Figure 3.2.2). 
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Time post BEZ235 treatment 
 
 
 
 
 
 
 
Figure 3.2.2. Following the daily administration of BEZ235, in the end of the study the animals 
were sacrificed and when the tumors were surgically removed, it was found a significant and an 
unexpected change in spleen morphology which aroused interest and for that reason surgically 
removed as well and measured. This effect was more pronounced the longer the mice were 
exposed to BEZ235. 
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Irrespective of the tumour background (endogenous or exogenous TRIB2 
protein expression), BEZ235 treatment induced a very significant morphology 
change. The BEZ235 treated mice show a highly significant reduction in spleen 
length that was dependent on the length of time that the animals were treated with 
BEZ235 (Figure 3.2.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.3: Following the daily administration of BEZ235, there was a significant change in spleen 
size. This effect was more pronounced the longer the mice were exposed to BEZ235. P values 
indicated were generated by two-tailed ANOVA analysis. (* P ≤ 0.05, ** P ≤0.01, *** P ≤0.001) 
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In addition to the noticeable length change, we also measured the weight of 
each spleen from the respective treatment groups (Figure 3.2.4). Consistent with 
significant length reducition following BEZ235 treatment, we note a concomitant 
reduction in spleen weight in 239T-empty BEZ235 treated mice. This significant 
difference was not observed in 293T-TRIB2 BEZ235 treated mice. The high P 
value (0.7058) is not due to a different dose of BEZ235 but rather the fact that 
293T-TRIB2 tumors did not respond to BEZ235 and as a consequence, the mice 
were sacrificed due to tumour burden, thus the did not have sustained daily 
exposure to BEZ235 unlike the majority of the 293T-empty tumour bearing mice 
who showed a noticeable response in almost all treated animals. 
 This can be noted in the 293T-TRIB2 BEZ treated spleens towards the right 
hand side of figure 3.2.2 where the size difference is noticeable compared to those 
on the left of the same figure. 
  
 
Figure 3.2.4.: Following the daily administration of BEZ235, there was a significant change 
in spleen weight in 239T-empty treated mice. This effect was more pronounced the longer 
the mice were exposed to BEZ235. P values indicated were generated by two-tailed 
ANOVA analysis. 
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3.3. The TRIB2 and AKT proteins interact both in vitro and in ex vivo 
clinical samples.  
  Our previous in vitro and our novel in vivo data indicate that TRIB2 status correlates 
with AKT activation. High TRIB2 cell lines display significantly elevated levels of 
pSer473-AKT and as a consequence of this have repressed FOXO3a activity 
(manuscript under review). This raised the interesting question as to whether the 
TRIB2 protein and AKT could interact. To address this question, we applied a number 
of methodologies including confocal microscopy, co-immunoprecipitation and in 
collaboration with Dr E. Kiss-Toth conducted protein fragment complementation 
assays (PCA)65–67 Our PCA studies showed a strong interaction between TRIB2 and 
AKT1 (Figure 3.3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1. Representative yellow fluorescent protein (YFP) complementation microscopy analysis 
assay for the assessment of the interaction between AKT1/2 and TRIB2. The leucine zipper Venus1 
and Venus2 (ZIPV1-V2) constructs were used as a positive control. BF indicates bright field, GFP 
indicates green fluorescent protein (with a very similar excitation spectrum as YFP for image 
acquisition). (generated in Sheffield by Prof. Kiss-Toth)  
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As a positive control, we included the protein JIP1 in this study as this is an 
established, known AKT interacting protein.68 Having observed this interaction, we 
next questioned the intensity of this interaction, asking if the interaction between 
TRIB2/AKT was higher, lower or similar to JIP1. Using FACS analysis (for yellow 
fluorescent protein [YFP]), the intensity of the complemented protein complex was 
evaluated (Figure 3.3.2). Strikingly, we observe that the interaction between AKT 
and TRIB2 was as intense as AKT/JIP1. 
Having noted that TRIB2 and AKT interact and that this interaction was as strong 
as the known AKT/JIP1 interaction, we questioned if we could detect this 
interaction in our in vitro cell lines without the requirement of conducting PCA.  
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Figure 3.3.2. Mean fluorescent intensity of YFP positive cells. One-way ANOVA with Dunnett’s 
multiple comparison test, n = 4 (* P ≤ 0.05, ** P ≤0.01, *** P ≤0.001). All analysis was conducted 
compared to zipV1trib3V2 (lane 1). 
 
Using our cell lines with high TRIB2 protein expression (exogenous [293T, 
U2OS], endogenous [SK-MEL28]) we conducted TRIB2 co-IP) CNIO antibody) and 
probed for either TRIB2 (SCBT antibody) or total-AKT. Strikingly, we note that 
there was a clearly detectable protein complex under normal cell growth conditions 
(i.e. in the absence of any inhibitors or chemotherapeutic). 
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Figure 3.3.3. Co-immunoprecipitation of TRIB2 or total AKT1 from indicated cell lines, (500 μg total 
protein lysate immunoprecipitated per lane) and separated by 8-12% SDS-PAGE. 
 
 
 
We confirmed the equivalent protein load for each Co-IP (Figure 3.3.4) and 
that TRIB2 and AKT interact. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.4. Total protein levels in each indicated cell line for co-IP targets (100 µg total protein 
loaded per lane and separated by 8-12% SDS-PAGE). 
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Having seen that TRIB2 and AKT interact in both an artificial assay (PCA) 
and in our in vitro cell line models, we questioned how clinically relevant this 
interaction could be. To this end, we obtained a number of stage IV metastatic 
melanoma samples and had these sectioned on a cryostat at Faro Hospital. We 
stained these sections for pSer473-AKT and TRIB2 addressing if in clinical patient 
samples there was co-localisation (Figure 3.3.5).  
Consistent with the PCA and in vitro co-IPs that we previously conducted, we 
note that there was significant co-localisation of AKT and TRIB2. Interestingly, 
whereas the previous studies examined TRIB2 interaction with total AKT, this co-
localization study demonstrated that not only does AKT and TRIB2 interact, that it 
is pSer473-AKT and TRIB2 that form a protein complex. This is under active 
investigation within our group (data unpublished/manuscript under review). 
 
  
Figure 3.3.5. :Representative immunofluorecent images of stage IV metastatic melanoma 
stained for pSer473-AKT1 (green) and TRIB2 (red) showing co-staining and interaction. The left 
row includes bright-field image for the sample. Yellow region indicate areas of co-localisation. 
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CHAPTER 4 
 
CONCLUSION  
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4. Conclusion 
 
Melanoma although not the most frequent skin cancer type, is the most fatal, 
aggressive, is the one with poorest prognosis, with low levels of effective response, 
due the fact that metastasize very fast, the tumors heterogeneity, and that the 
patients acquire drug resistance to almost all treatments. For these reasons, 
researchers have been looking for melanoma biomarkers, with only one, LDH 
approved by the FDA.  
Previous data from our group showed that in malignant melanoma there is an 
over expression of TRIB2 at both the mRNA and protein level, suggesting both an 
oncogenic role in melanoma and a potential biomarker.  
         Before being used in clinical trials, drugs must be tested in cell lines, in this 
case preferably melanoma cell lines (in vitro model) and then in animal models (in 
vivo studies) and my project allowed me to test not only in cell lines, but also in in 
vivo with xenograft mice and ex vivo with clinical samples from patients with the 
disease. The obtained results show over expression of TRIB2 in different 
melanoma cell lines, once again correlating previous lab results. This over 
expression, seen mainly in melanoma, suggests that TRIB2 may be a good 
prognostic biomarker for malignant melanoma.  Published and unpublished data 
from our group already pointed to an association between TRIB2 and drug 
resistance and this project allowed me to see that TRIB2 confers resistance to 
PI3K/mTOR inhibitor drug BEZ235. One of the biggest questions of my research 
was about the mechanism behind drug resistance due to TRIB2 present in 
PI3K/AKT signaling pathway and the answer could be the fact of TRIB2 is having 
an action downstream of PI3K, and once the drugs act upstream, TRIB2 could be 
activating constantly AKT through its interaction. However much the drug is 
administered to the patients will have no effect (figure 4.1.1) 
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 Figure 4.1.1:  AKT/TRIB2 interaction and FOXO3a inactivation. 
 
 
 
Other interesting result that corroborates this hypothesis, is the fact that 
when we see an overexpression of TRIB2, there is an increase of the active form 
of AKT (pSer473-AKT) both in clinical, in vitro and in in vivo samples. To turn this 
story more interesting, Co-IP demonstrated that TRIB2 and AKT interact, so there 
really is a relation between higher levels of TRIB2 and AKT activation.  
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To understand how this interaction is done, our lab is seeing if TRIB2 
interacts with AKT through COP1 domain (unpublished data). Our results show as 
well a correlation between TRIB2 and AKT interaction and a decrease of FOXO3a 
expression, once AKT phosphorylates FOXO3a, causing  FOXO3a exportation 
from the nucleus to the cytoplasm, resulting in lower levels of pro-apoptotic genes 
like BIM and genes involved in cell cycle arrest such as p27.  
So if there is none expression of this genes, cancerous cells will keep 
proliferating, growing, avoiding cell death allowing tumor progression.  
In case of BEZ235, will be more effective if the patient doesn’t have an 
overexpression of TRIB2, in contrary there is no advantage in administering this 
drug, as it will have no beneficial effect and the patient will be subject to 
unnecessary cytotoxic effects. Ideally, a patient screening to identify if there is an 
overexpression of TRIB2 will avoid giving unnecessary, ineffective and aggressive 
treatments to the patients, promoting a personalizes diagnosis and treatment. 
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4.1. Future directions 
These results highlighted how TRIB2 interacts with AKT in PI3K/AKT 
pathway, and for future directions it would be crucial to keep evaluating TRIB2 
interactions through Co-IP, optimizing this process. ´ 
Would be important as well to clarify the mechanism of drug resistance by 
TRIB2 to somehow reverse this process avoiding cancer progression and 
promoting an increase of life quality to the patients, perhaps an increase of patients 
overall survival. Are needed more clinical samples analyses, a larger number of 
them to elucidate the characterization of PI3K/AKT/ TRIB2 to know how even in the 
present of PI3K inhibitors, how TRIB2 acts in this pathway. 
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Figure A.1: Mounting solution protocol for immunofluorescence. 
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          Figure A.2: Poster done by me for the Oncobiology Retreat Session and Poster presentation. 
 
 
